Lundbeck Reportedly Explores Potential Takeover of Xeris Pharmaceuticals

Danish pharmaceutical group H. Lundbeck A/S has reportedly expressed interest in a potential acquisition of Chicago-based Xeris Pharmaceuticals Inc. (NASDAQ:XERS), according to a Bloomberg report citing people with knowledge of the matter. The development signals Lundbeck's potential ambition to diversify beyond its core central nervous system portfolio.

Acquisition Talks

Lundbeck has reportedly engaged financial advisors to evaluate a potential transaction for the U.S. biopharmaceutical company. However, discussions are said to be in a preliminary stage, and there is no certainty that a formal offer will be made or that a deal will materialize.

With a market capitalization of approximately 43.3 billion Danish kroner (about $6.6 billion), Lundbeck has the financial scale to pursue a company like Xeris, which has a market value of around $1.8 billion. Shares of Xeris have gained nearly 20% over the past 12 months.

Company Positions and Strategic Fit

Ad

In response to the report, a spokesperson for Xeris told Bloomberg that the company is "not for sale" and remains focused on its strategy of "developing and commercializing" its therapeutic products to improve patient lives. Xeris is a commercial-stage company specializing in therapies for endocrinology and rare diseases.

Its portfolio includes three approved treatments, most notably Recorlev for Cushing's syndrome. Xeris is also developing a once-weekly injection for hypothyroidism as an alternative to daily oral medications. An acquisition would allow Lundbeck, which traditionally focuses on neurological and psychiatric disorders like Parkinson's and schizophrenia, to expand into the rare endocrine disease market and acquire specialized formulation technology.

Market Implications

A potential deal aligns with previous strategic interests shown by Lundbeck's controlling shareholder, the Lundbeck Foundation, which has invested in research for brain-targeted injectables for metabolic diseases. For investors, the reported interest highlights ongoing consolidation trends in the pharmaceutical sector, where established players seek to acquire innovative assets to fuel growth and diversify revenue streams. Market participants will be watching closely to see if Lundbeck proceeds with a formal proposal or if Xeris continues on its independent path.